drugset / Trial / NCT00493194

Fibrosis in Renal Allografts

NCT00493194

RandomizedParallel-groupOpen-labelTreatment

Summary

This prospective, randomized study, comparing sirolimus to cyclosporine in renal transplant recipients, has two major objectives: 1. -To determine the incidence and the degree of interstitialfibrosis and arteriosclerosis, as wel as the glomerular volume in protocol biopsies at 6 months in sirolimus-and in cyclosporine-treated renal allograft recipients, by means of quantitative computerized image analysis. * To determine the prognostic implication of these morphologic changes. 2. To study the expression of genes, involved in inflammation and fibrosis, in protocol biopsies at 6 months in sirolimus-and cyclosporine-treated renal allograft recipients.

Timeline

Start
2005-05
Primary completion
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide
Subject Sirolimus Small molecule
Background Daclizumab Monoclonal antibody Intravenous